Prof. Dr. Luis-Antonio Alvarez-Sala Walther has been a Full Professor of Medicine at the Faculty of Medicine of the Complutense University of Madrid since 2002. He is also the Head of the Internal Medicine Section at the Gregorio Marañón General University Hospital (HGUGM), and is co-responsible for the Lipids and Hypertension Unit. He began managing patients with lipid disorders in 1985 with Prof. De Oya at the Jiménez Díaz Foundation in Madrid, where he had previously completed his residency in internal medicine and his medical studies at the Autonomous University of Madrid, where he received his doctorate in 1992. In 1999, he moved to HGUGM with Prof. Millán, where he has continued until now. His work in lipid consultation has been related to patients with moderate-to-severe hypercholesterolemia or hypertriglyceridemia and in patients with multiple cardiovascular risk factors, whether in primary or secondary prevention. He is currently accredited as a Professor, with four research sections recognized by ANECA and three five-year teaching periods recognized by the Ministry of Education. He has participated in the clinical development of different drugs involved in vascular or lipid or carbohydrate metabolic risk through clinical trials, such as fibrates, statins, ezetimibe, PCSK9 inhibitors (evolocumab, alirocumab, and bococizumab), and apo CIII gene silencing, such as ISGLT2, as well as with the new direct oral anticoagulants: rivaroxaban, apixaban, and betrixaban.
Research Keywords & Expertise
Diabetes
Internal Medicine
cardiovascular risk
metabolic disorders
Thrombosis prevention
Short Biography
Prof. Dr. Luis-Antonio Alvarez-Sala Walther has been a Full Professor of Medicine at the Faculty of Medicine of the Complutense University of Madrid since 2002. He is also the Head of the Internal Medicine Section at the Gregorio Marañón General University Hospital (HGUGM), and is co-responsible for the Lipids and Hypertension Unit. He began managing patients with lipid disorders in 1985 with Prof. De Oya at the Jiménez Díaz Foundation in Madrid, where he had previously completed his residency in internal medicine and his medical studies at the Autonomous University of Madrid, where he received his doctorate in 1992. In 1999, he moved to HGUGM with Prof. Millán, where he has continued until now. His work in lipid consultation has been related to patients with moderate-to-severe hypercholesterolemia or hypertriglyceridemia and in patients with multiple cardiovascular risk factors, whether in primary or secondary prevention. He is currently accredited as a Professor, with four research sections recognized by ANECA and three five-year teaching periods recognized by the Ministry of Education. He has participated in the clinical development of different drugs involved in vascular or lipid or carbohydrate metabolic risk through clinical trials, such as fibrates, statins, ezetimibe, PCSK9 inhibitors (evolocumab, alirocumab, and bococizumab), and apo CIII gene silencing, such as ISGLT2, as well as with the new direct oral anticoagulants: rivaroxaban, apixaban, and betrixaban.
Advance your academic career, collaborate globally, and expand your network—
join now
!
Well done!
